Heart failure as an adverse effect of infliximab for Crohn's disease: A case report and review of the literature

Thais Gagno Grillo*, Luciana Rocha Almeida, Rodrigo Fedatto Beraldo, Mariana Barros Marcondes, Diego Aparecido Rios Queiróz, Daniel Luiz da Silva, Rodrigo Quera, Julio Pinheiro Baima, Rogerio Saad-Hossne, Ligia Yukie Sassaki

*Autor correspondiente de este trabajo

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

7 Citas (Scopus)


Background Anti-tumor necrosis factor agents were the first biologic therapy approved for the management of Crohn's disease (CD). Heart failure (HF) is a rare but potential adverse effect of these medications. The objective of this report is to describe a patient with CD who developed HF after the use of infliximab. Case Summary A 50-year-old woman with a history of hypertension and diabetes presented with abdominal pain, diarrhea, and weight loss. Colonoscopy and enterotomography showed ulcerations, areas of stenosis and dilation in the terminal ileum, and thickening of the intestinal wall. The patient underwent ileocolectomy and the surgical specimen confirmed the diagnosis of stenosing CD. The patient started infliximab and azathioprine treatment to prevent post-surgical recurrence. At 6 mo after initiating infliximab therapy, the patient complained of dyspnea, orthopnea, and paroxysmal nocturnal dyspnea that gradually worsened. Echocardiography revealed biventricular dysfunction, moderate cardiac insufficiency, an ejection fraction of 36%, and moderate pericardial effusion, consistent with HF. The cardiac disease was considered an infliximab adverse effect and the drug was discontinued. The patient received treatment with diuretics for HF and showed improvement of symptoms and cardiac function. Currently, the patient is using Conclusion This reported case supports the need to investigate risk factors for HF in inflammatory bowel disease patients and to consider the risk-benefit of introducing infliximab therapy in such patients presenting with HF risk factors.

Idioma originalInglés
Páginas (desde-hasta)10382-10391
Número de páginas10
PublicaciónWorld Journal of Clinical Cases
EstadoPublicada - 26 nov. 2021
Publicado de forma externa

Nota bibliográfica

Publisher Copyright:
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.


Profundice en los temas de investigación de 'Heart failure as an adverse effect of infliximab for Crohn's disease: A case report and review of the literature'. En conjunto forman una huella única.

Citar esto